Cynata Therapeutics (CYP) Q3 2025 TU earnings summary

Executive summary

• Maintained a strong cash position of AUD 8.5 million as of March 2025, providing runway through mid to H2 2026 and supporting major clinical trial readouts.

• Advanced clinical pipeline includes four active programs: osteoarthritis (phase III), graft-versus-host disease/aGvHD (phase II), diabetic foot ulcers (DFU, phase I completed), and kidney transplantation (phase I/II).

• Published peer-reviewed studies highlight Cymerus MSCs' unique protein secretomes and superior immunomodulatory effects compared to donor-derived MSCs.

• Major upcoming catalysts include phase II GvHD results in late 2025, phase III osteoarthritis results in H1 2026, and kidney transplantation cohort 1 data in 2025.

• Sector validation and increased partner engagement following Mesoblast's FDA approval for pediatric GvHD and active participation in major biotech initiatives.

Financial highlights

• Cash balance of AUD 8.5 million at quarter end, with runway into mid/H2 2026.

• Share price as of 2 May 2025: A$0.195; market capitalisation: ~A$44 million.

• Net operating cash outflows for the quarter were $2.1 million; $102k net cash from financing activities.

• Top 20 shareholders hold approximately 47% of shares on issue.

• No outstanding loan or credit facilities at quarter end.

Outlook and guidance

• Anticipates significant milestones with GvHD and osteoarthritis trial results within the next year, and kidney transplantation cohort 1 data in 2025.

• Ongoing engagement with potential partners and readiness for commercial activities post-trial readouts.

• Cash runway expected to last into mid/H2 2026.